Extension Study Demonstrates Durable Benefits of Stanza for Fibromyalgia

Swing Therapeutics announced today the follow-up results from the PROSPER-FM study of Stanza, demonstrating the durability of the treatment for fibromyalgia symptoms out to 12 months. The original study, published in The Lancet, validated Stanza’s digital behavioral treatment for fibromyalgia symptoms in the initial 12-week period. Building on these findings, the extension study evaluated the …